Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
MK-0482 binds to ILT3 and prevents binding of ILT-3 ligands, leading to inhibition of ILT-3 dependent signaling which may lead to activation of the antitumor immune response (NCI Drug Dictionary).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|MK-0482 + Pembrolizumab||MK-0482 Pembrolizumab||0||1|